Your session is about to expire
← Back to Search
Immunotherapy + Pembrolizumab for Head and Neck Cancer (BelieveIT-201 Trial)
BelieveIT-201 Trial Summary
This trial will evaluate if two treatments and pembrolizumab can help people with head and neck cancer before surgery to reduce risk of recurrence and improve survival.
BelieveIT-201 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.BelieveIT-201 Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What adverse effects may result from the combined use of TransCon TLR7/8 Agonist and pembrolizumab?
"Taking into account the Phase 2 status of this intervention, our team at Power considers TransCon TLR7/8 Agonist in combination with pembrolizumab to be relatively secure and gave it a score of two."
Are new participants actively being sought for this scientific research?
"Affirmative, clinicaltrials.gov displays that this trial is actively enrolling participants. First posted on September 29th 2023 and last updated on October 12th 2023, the study requires 92 people to be recruited from a single medical centre."
How many test subjects are involved in the ongoing clinical research?
"Affirmative. According to clinicaltrials.gov, this examination is recruiting participants since its post date of September 29th 2023 and last updated on October 12th 2023. An approximate 92 persons need to be recruited from 1 site for the trial's completion."
Share this study with friends
Copy Link
Messenger